1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort

Bai, L-Y.; Chiu, C-F; Kadowaki, Shigenori; Robert, Marie; Hara, Hiroki; Hong, Min Hee; Bergamo, F.; Pernot, Simon; Cunningham, Deborah; Lin, Cai; Keam, Bhumsuk; Matsumura, Yasuhiro; Enya, K.; Waxman, Ian M.; Jin, Lixian; Ngo, D.; Drews, U.; Mancao, C.; Berre, M-A. Le; Kato, Kazúo

doi:10.1016/j.annonc.2022.07.1327

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a phase II multiple cohort trial of regorafenib, a novel oral multi-kinase inhibitor including angiogenic kinases, in combination with nivolumab in advanced solid tumors, the ESCC cohort showed an ORR of 43% and median PFS of 6.9 months in 30 patients. 268 Currently, there are several ongoing trials combining ICI with apatinib (NCT05049681), anlotinib (NCT05038813, NCT05013697, NCT04797507, and NCT04503967), famitinib (NCT04866381), and cabozantinib (NCT05007613; Table 6 ). Lenvatinib targets VEGFR 1, 2, and 3, PDGFR α, FGFR, c-KIT, and RET tyrosine kinases.…”

Section: Potent Molecular-targeted Therapy For Patients With Esccmentioning

confidence: 99%

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a predominant histological subtype of EC that has unique etiology, molecular profiles, and clinicopathological features. Although systemic chemotherapy, including cytotoxic agents and immune checkpoint inhibitors, is the main therapeutic option for recurrent or metastatic ESCC patients, the clinical benefits are limited with poor prognosis. Personalized molecular-targeted therapies have been hampered due to the lack of robust treatment efficacy in clinical trials. Therefore, there is an urgent need to develop effective therapeutic strategies. In this review, we summarize the molecular profiles of ESCC based on the findings of pivotal comprehensive molecular analyses, highlighting potent therapeutic targets for establishing future precision medicine for ESCC patients, with the most recent results of clinical trials.

show abstract

Section: Potent Molecular-targeted Therapy For Patients With Esccmentioning

confidence: 99%

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…16,36 Table 1 summarizes the recent clinical trials that have investigated the clinical benefit of nivolumab. 16,20,[36][37][38][39] The ATTRACTION-1 trial…”

Section: Nivolumab As Second-or Later-line Treatmentmentioning

confidence: 99%

“…In addition to the mainstream combination of ICIs and chemotherapy for patients with OSCC, the combination of ICIs with molecular-targeted agents is also being assessed. A multicentre, phase 2 study evaluating regorafenib plus nivolumab combination therapy showed an objective response rate of 43% in the treated advanced OSCC cohort 37. ICI combination trials are on-going, namely: the LEAP-014 study, an openlabel, randomized phase 3 trial of lenvatinib and pembrolizumab plus chemotherapy as first-line therapy in OSCC ( ClinicalTrials.…”

mentioning

confidence: 99%

Nivolumab Combination Therapy for the Treatment of Unresectable Advanced or Metastatic Oesophageal Squamous Cell Carcinoma

Yoshinami¹,

Yamamoto²,

Kato³

2023

Oncology &Amp; Haematology

View full text Add to dashboard Cite

Oesophageal cancer (OC) is the seventh most common malignancy worldwide, and there are few effective treatment options for advanced OC. Fluoropyrimidine and platinum-based chemotherapy has been the standard first-line treatment for advanced oesophageal squamous cell carcinoma (OSCC) but the survival outcomes are poor. Therefore, there is a need to develop new, more effective drugs. Immune checkpoint inhibitors (ICIs) have emerged as a new standard treatment for several malignancies. Nivolumab, a human monoclonal immunoglobulin G4 antibody that inhibits programmed cell death protein-1, has been developed for the treatment of advanced OSCC. Nivolumab monotherapy demonstrated clinical efficacy and safety in patients with OSCC in the ATTRACTION-3 trial, and was approved by the United States Food and Drug Administration as later-line treatment for patients with previously treated OSCC, regardless of programmed cell death protein-1 ligand expression status. Recently, the CheckMate 648 trial demonstrated the efficacy and safety of both an ICI in combination with chemotherapy, and a dual ICI combination, as first-line treatment for patients with advanced OSCC. This review discusses the current status of nivolumab combination therapy for patients with advanced OSCC, and future perspectives.

show abstract

Chemo-immunotherapy in advanced esophageal squamous cell carcinoma: present and future

Wang

2023

Holist Integ Oncol

View full text Add to dashboard Cite

With the recent progress in scientific research, the combination of chemotherapy and PD-1 blockade has become the new standard-of-care first-line treatment for patients with advanced esophageal squamous cell carcinoma. This short review highlights the recent important findings and challenges regarding the optimal chemotherapy backbone in combination with PD-1 blockade, biomarkers for predicting the efficacy of chemo-immunotherapy, treatment strategies beyond chemo-immunotherapy, and secondary resistance to chemo-immunotherapy in advanced esophageal squamous cell carcinoma.

show abstract

1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort

Cited by 5 publications

References 0 publications

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

Nivolumab Combination Therapy for the Treatment of Unresectable Advanced or Metastatic Oesophageal Squamous Cell Carcinoma

Chemo-immunotherapy in advanced esophageal squamous cell carcinoma: present and future

Contact Info

Product

Resources

About